Clinical trial
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac…
NCT00475072 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00475072 |
|---|---|
| Title | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C. |
| Official title | An Open Label Study to Evaluate the Safety and Effect on Sustained Virological Response of PEGASYS Plus Ribavirin in Patients With Hemophilia A and Chronic Hepatitis C |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | peginterferon alfa-2a [Pegasys], ribavirin |
| Enrollment | 14 |
| Start date | Jun 1, 2003 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | May 17, 2007 |
| Last update posted | Nov 1, 2016 |
| Countries | Mexico |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: